공시 • Jun 09
Smith+Nephew Announces Completion of First Clinical Cases with Next Generation CORI XT Handheld Robotics Platform Across Knee and Shoulder Arthroplasty Smith+Nephew announced the completion of the first clinical cases performed using the next-generation CORI XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty and reflect Smith+Nephew’s Skill Amplified approach to handheld robotics—designing technology to support and enhance surgeon expertise while preserving surgeon control, clinical judgment, and efficient workflows. The first shoulder arthroplasty cases using CORI XT Platform were performed at Duke Health by a surgical team led by Dr. Christopher Klifto. Dr. Klifto utilized CORI SHOULDER Handheld Robotic Arthroplasty in combination with the AETOS Shoulder System. CORI SHOULDER offers a complete robotic procedure, supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures. Building on this initial clinical experience, Dr. Bertrand Kaper completed the first CORI XT shoulder arthroplasty cases in an ambulatory surgery center (ASC) setting at North Valley Surgery Center in Scottsdale, Arizona, further expanding the use of CORI XT Platform across care environments, and highlighting the versatility and fit of the CORI XT Platform in an ASC setting, and the well-suited nature of handheld robotics to shoulder arthroplasty. The first knee replacement procedures performed using the CORI XT Handheld Robotics Platform were completed at NYU Langone Health by Dr. Ran Schwarzkopf, orthopedic surgeon and joint replacement specialist. These cases mark the first clinical use of CORI XT Platform in knee arthroplasty and an important milestone in the platform’s broader rollout as its applications continue to expand. CORI XT Platform is designed to provide the benefits of robotic assistance while preserving the efficiency and familiarity of established surgical workflows. Its handheld form factor enables surgeons to access robotic guidance and execution support without disrupting procedural flow or adding operational complexity to the operating room. As part of Smith+Nephew’s Skill Amplified robotics approach, CORI XT Platform is designed to enhance accuracy1 while maintaining surgeon control, tactile feedback, and decision-making throughout the procedure. By integrating naturally into how surgeons already operate, the platform supports consistent execution without requiring changes to operating room setup or procedural workflow. With its compact footprint and mobility, CORI XT Platform is suited for use across both hospital and ambulatory surgery center environments.2 The system integrates with Smith+Nephew’s CORIOGRAPH Pre-Operative Planning and Modeling Services to support patient-specific planning while enabling efficient intraoperative execution. The CORI XT Platform is part of Smith+Nephew’s broader MTECH (Musculoskeletal Technologies to Enhance Care and Healing) portfolio, spanning robotics, navigation, visualization, and enabling technologies across orthopaedic surgery. CORI HIP Handheld Robotic Arthroplasty indication is under development. 1. Bollars P, Janssen D, De Weerdt W, et al. Improved accuracy of implant placement with an imageless handheld robotic system compared to conventional instrumentation in patients undergoing total knee arthroplasty: a prospective randomized controlled trial using CT-based assessment of radiological outcomes. 공시 • Jun 02
Smith+Nephew launch next generation LEAF™ Patient Monitoring System Smith+Nephew announced the US launch of next generation LEAFPatient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence. Every year, approximately 60,000 annual deaths in the US are attributed to HAPIs, placing a $26.8 billion annual burden on the nationwide economy. For individual hospitals, that can mean millions of extra dollars spent on extended lengths of stay and patient readmissions. Staff shortages, workload pressures, and limited data access all contribute to protocol inconsistencies, while clinicians face growing pressure to improve patient safety and control costs, without compromising outcomes. Positioned at the forefront of HAPI prevention, LEAF Next Generation is a cloud-hosted solution which features a redesigned and enhanced user interface. Designed in consultation with multidisciplinary nursing teams, LEAF Next Generation helps to ensure that at-risk patients get the necessary care at the appropriate time, with improved turn quality and protocol adherence. The system seamlessly integrates with hospital electronic medical records (EMRs), helping nurses to adhere to turning protocols using real time data and reporting that quickly identifies at-risk patients. Hosted securely on Smith+Nephew’s cloud, with access via any hospital-approved device, clinicians are able to focus on patient care rather than system maintenance. The system's user interface enables intuitive workflow navigation with document automation which allows nurses to quickly access critical information and streamline patient management. Interdisciplinary teams benefit from instant access to patient-level insights, alongside a hospital-wide view to assess performance over time. This helps to ensure continuous delivery of high-quality care is maintained at all times. The LEAF system has already transformed HAPI prevention, turning evidence into action compared to the standard of care. Each year, it monitors over 150,000 patients, reducing the odds of HAPIs by up to 73% and delivering up to $1.8 million in estimated savings in just one critical care facility. 공시 • May 06
Smith & Nephew plc to Report Q2, 2026 Results on Aug 04, 2026 Smith & Nephew plc announced that they will report Q2, 2026 results on Aug 04, 2026 공시 • Apr 22
SMITH & NEPHEW PLC Announces New Data for Cartiheal Agili-C Cartilage Repair Implant SMITH & NEPHEW PLC announced further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care for all time points out to 60 months. Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5-years. Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant. Smith+Nephew's FDA-approved CARTIHEAL Implant is revolutionizing the cartilage repair landscape with the implant's broad indication allowing physicians to treat patients who previously may not have had access. The implant recently received a Category I Current Procedural Terminology (CPT) code for procedures that will go into effect on January 1, 2027. 공시 • Apr 10
Smith+Nephew Announces Significant Outcome Improvements for Regeneten Bioinductive Implant in Partial-Thickness Rotator Cuff Tears Smith+Nephew announced compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation. Compared with a traditional suture anchor repair, early recovery time was halved for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks, Office work: 1.7 vs 3.6 weeks (p=0.009), Moderate-intensity household chores: 3.8 vs 8.4 weeks. The study, recently published in the Orthopaedic Journal of Sports Medicine, also concluded that REGENETEN Implant patients enjoyed a better quality of life at 6 weeks and 3 months, and high rates of tendon healing at 1 year, comparable to suture anchor-based repairs. This is the third RCT demonstrating that the REGENETEN Bioinductive Implant improves outcomes versus traditional rotator cuff repair techniques. With more than 250,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs. This evidence follows the recent revision to the American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the ‘Management of Rotator Cuff Injuries’ which highlights the value of bioinductive implants in rotator cuff repair based on an independent analysis of studies. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair. 공시 • Mar 17
Smith & Nephew plc, Annual General Meeting, May 06, 2026 Smith & Nephew plc, Annual General Meeting, May 06, 2026. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye., watford 8ye., watford United Kingdom 공시 • Mar 11
Smith+Nephew Launches Allevyn Complete Care Foam Dressing Smith+Nephew recently announced the launch of ALLEVYN COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage and disruption by fewer dressing changes, and protecting vulnerable skin are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing delayed healing and complications that impact daily life. Studies report up to one in 10 hospitalised patients are affected by pressure injuries, with hospital-acquired pressure injuries associated with an average of 9.5 additional days of hospital stay. Pressure injuries and chronic wounds continue to place a significant burden on the broader healthcare system. ALLEVYN COMPLETE CARE Dressing’s proprietary technologies have advanced capabilities that are designed to help clinicians care with confidence. The dressing was developed to address the needs of both wound management and pressure injury prevention, informed by collaboration with healthcare professionals and patients worldwide. It is proven to lock in significantly more exudate than other foam dressings while keeping over 99% of bacteria away from the wound bed. This minimises leakage, enables longer wear times for undisturbed healing, and has potential to release over 10% of valuable nursing time. Unbonded sliding layers within the dressing absorb up to 93% of mechanical energy, helping to reduce the risk of pressure injury by over 65%. ALLEVYN COMPLETE CARE Dressing’s unbonded multilayer structure delivers a distinct mode of action that helps dissipate shear forces before they reach the skin and underlying soft tissues. This pioneering technology protects soft tissue and minimises the risk of developing a pressure injury. ALLEVYN COMPLETE CARE Dressing is available in five different shapes and a variety of sizes to meet a diverse range of wound care needs. Initially available in the US, the dressing will be launching in many European and other international markets in 2026 as the company continue to support patients’ unique needs, and shape what’s possible in wound care. 공시 • Mar 04
Smith+Nephew to Showcase Advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma Technologies During AAOS 2026 Smith+Nephew announced it will feature handheld robotics and digital solutions for hip, knee and shoulder in addition to innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. Some of the company’s latest Orthopaedics advancements and highlighted technologies include: Handheld Robotics: Optimizing and Personalizing Surgery. As the leader in handheld robotics, the CORI? Surgical System delivers a digital surgery ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative data management solution. The entire robotics ecosystem is designed to amplify the surgeon experience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty. Smith+Nephew’s CORIOGRAPH? Pre-Op Planning and Modeling Services enables optimization of handheld robotic knee and shoulder arthroplasty and computer guided hip – further personalizing surgery for both surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI Surgical System supports several image modalities - allowing for a new dimension of pre-operative planning for each individual patient - and supporting the intra-operative surgical workflow. In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modeling of patient motion is important in planning implant position and advanced simulated activities of daily living. CORI XT is required for shoulder application. CORI SHOULDER Robotic Shoulder Arthroplasty with the AETOS? Shoulder System: Differentiated Technology for Personalized Care. In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmet needs of surgeons who demand both accuracy and procedural efficiency. The system is specifically optimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platform technology and supports robotic preparation of both humeral and glenoid execution for shoulder arthroplasty. Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution that supports seamless integration and workflow efficiencies for shoulder arthroplasty. The procedure represents a significant leap forward in the shoulder arthroplasty space, perfectly suited for the constraints of the anatomy and supported by a portable footprint for flexibility in the hospital or ASC. Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed, performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, please visit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplasty at AAOS in Booth #839. Advanced Implant Science. Get the latest clinical data and insights on our flagship implant options for hip, knee and shoulder arthroplasty including recent additions to our portfolio such as LEGION? Total Knee Medial Stabilized System, CATALYSTEM? Primary Hip System and the AETOS Shoulder System stemless option. Trauma Advancements. From reduction to fixation, the EVOS? LARGE & PERIPROSTHETIC Plating System has evolved to give surgeons stability and flexibility with one screw design for threaded locking, and variable-angle locking and compatibility with the EVOS Cabling System. We will also be expanding the EVOS portfolio this year with the launch of the EVOS PELVIC System. TRIGEN? MAX Tibia Nailing System is the only system to give trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options. Come visit Smith+Nephew at Booth #839 and hear about the expansion of TRIGEN MAX Tibia this year. Smith+Nephew has also recently signed distribution agreements with SI-BONE, focused on their innovative iFuse TORQ portfolio for pelvic fractures and RMR Ortho for the A’TOMIC™ Nitinol Fixation System, a compression fixation option for trauma cases. At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASC offering—an end-to-end solution designed to support both de novo ASC development and the modernization of existing facilities. This comprehensive model enables customers to finance, design, build, equip, and optimize their centers through one coordinated, streamlined pathway. Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity Health Centers, and STERIS, we are bringing best-in-class expertise and technologies together into a single, aligned delivery model—helping customers accelerate timelines, reduce complexity, and drive operational performance from day one. 공시 • Jan 22
Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc. Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026.
Pran Jha, Joe Michaels, Danielle Haikal, Hannah Ellis, Kathy Jara, McKenna Chadwick, Parker Whitlow, Lauren Grau, Dina Kang, Patrick Donaldson, Lauren Gallagher, Amanda Casanueva, Nicholas Carballo, Cathryn Le Regulski, Kristina Daisak, Torrey Cope, Kelly Cho, Lauren Limbach, Elizabeth Hardcastle, Melody Mostow, Gabrielle Feliciani, Ash Nagdev, Sasha Hondagneu-Messner, Liz McCloy, Brandon Bryer, Suresh Advani and George Chen of Sidley Austin LLP acted as legal advisors for Smith & Nephew plc.
Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc. on January 21, 2026. 공시 • Jan 13
Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million. Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026. 공시 • Nov 06
Smith & Nephew plc to Report Fiscal Year 2025 Results on Mar 02, 2026 Smith & Nephew plc announced that they will report fiscal year 2025 results on Mar 02, 2026 공시 • Oct 28
Smith+Nephew Announces Findings from A Newly Published, First-Of-Its-Kind comparative Study of Single-Use Negative Pressure Wound Therapy Devices inorthopedic and Cardiovascular Surgery Smith+Nephew announced findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™? Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to the PrevenaTM -125 mmHg sNPWT device. An estimated 313 million surgical procedures are performed worldwide each year, with the number continuing to rise. In the United States, surgical site infections (SSIs) occur in approximately 2% to 4% of patients undergoing inpatient procedures. In relation to PrevenaTM sNPWT (-125mmHg), use of PICO sNPT (-80mmHg) resulted in the following key study findings: Cardiovascular Surgery (5,000+ patients) 57.8% relative reduction in wound dehiscence risk (P 9.1% relative reduction in LoS (6.33 days vs. 6.86 days) (P 10.34% relative reduction in admission-related costs and 13% lower expenditures within three months post-surgery (P Orthopedic Surgery (17,000+ patients) 63.9% relative reduction in wound deHiscence incidence (p 29.7% relative reduction in LoS(2.43 days vs. 3.10 days) (pp 21.95% relative reduction in mean index admission cost and a 21% reduction at 30- and 90-day post-surgery. These findings complement the growing evidence supporting prophylactic use of incisional negative pressure wound therapy (iNPWT) across surgery. A recent meta-analysis presented at the International Consensus Meeting 2025 concluded that "The use of iNPWT is recommended to minimize the risk of SSI in adult patients with primarily closed surgical incisions after lower extremity/acetabular fracture surgery and joint arthroplasty of the hip and knee." These findings are aligned with the global recommendations including NICE4, WHO5 and the ACS/SIS6 guidelines, all of which recommend the use of iNPWT for the purpose of reducing the risk of SSI for at risk patients. 공시 • Sep 13
Smith+Nephew Unveils Major Clinical Evidence and Patient Access Updates for its REGENETEN Bioindictive Implant Smith+Nephew announced new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout the body: AAOS Clinical Practice Guideline (CPG) on the Management of Rotator Cuff Injuries: For the first time, recent updates to the American Academy of Orthopaedic Surgeons (AAOS) CPG on the Management of Rotator Cuff Injuries highlight the value of bioinductive implants in rotator cuff repair, based on independent analysis of studies: AAOS CPGs provide evidence-based recommendations for current orthopaedic diagnostic, treatment, and postoperative procedures; Analyzing RCTs for bioinductive implants, AAOS have issued a StrongRecommendation that: ‘The use of bioinductive tendon implants to augment rotator cuff repair, or as an alternative to standard repair, can lead to lower re-tear rates and better patient reported outcomes.’ Randomized Controlled Trial (RCT) Results: Two-year results of the MALLAMANGUITO RCT from Dr. Miguel A. Ruiz Ibán and colleagues demonstrated a sustained 65% relative reduction in re-tear rates when using the REGENETEN Bioinductive Implant to augment repair of full-thickness rotator cuff tears: Two-year re-tear rates were 12.3% (7/57) with the REGENETEN Implant vs. 35.1% (20/57) with standard repair (p=0.004).These results build on previously reported 1-year results which have already made a significant impact in supporting patient access and adoption. Extra-articular Ligaments: For the first time, Smith+Nephew is able to market the REGENETEN Bioinductive Implant for extra-articular ligament injuries in the US. This new indication expansion offers opportunities to reach more patients with soft tissue injuries throughout the body. It will initially focus on hip capsule repair with abundant opportunities for future expansions in other extra-articular ligament repairs.With more than 150,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for the more than 1 million people having tendon or extra-articular ligament repair each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs and support natural healing processes. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair. 공시 • Sep 03
Smith+Nephew Extends Advanced Wound Bioactives Portfolio with US Launch of Centrio Platelet-Rich-Plasma System Smith+Nephew announced the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. Due to a National Coverage Determination (NCD) made effective April 2021, autologous PRP for the treatment of chronic non-healing wounds for diabetic patients has CMS coverage, when prepared by devices whose indications include the management of exuding cutaneous wounds, such as diabetic ulcers.1 The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single draw of a patient's blood. CENTRIO PRP system has demonstrated efficacy in two randomized, controlled clinical trials2,3, making it a strong fit in Smith+Nephew's clinically proven portfolio. The CENTRIO PRP system will premiere at the Smith+Nephew booth during the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada from September 3-6. Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States. 공시 • Aug 28
Smith & Nephew plc Announces Dr Garheng Kong Will Join as an Independent Non-Executive Director and Member of the Audit Committee, Effective September 1, 2025 Smith & Nephew plc announced that Dr Garheng Kong will join the Board as an independent Non-Executive Director and a member of the Audit Committee with effect from 1 September 2025. Garheng is currently managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director of Laboratory Corporation of America (LabCorp) and a non-executive director of Xeris Biopharma Holdings Inc, Lunit Inc. and IKS Health. Garheng was previously managing general partner of Sofinnova Investments Inc. and served as a non-executive director of Venus Concept, Inc, Alimera Sciencesand Avedro Inc. and as chair of Histogenics Corporation. 공시 • Jul 07
Smith+Nephew Announces the Release of Its Q-Fix Knotless All-Suture Anchor for Soft Tissue-To-Bearing Indications Across Multiple Joint Spaces Including Shoulder, Hip, Hip, and Foot & Ankle Smith+Nephew announced the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices, the new Q-FIX KNOTless All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS all-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including: Market-leading strength in all-suture anchor fixation1-5 and ultra-low displacement1,6-10 Consistent deployment4,11,12, Best-in-class soft tissue security with suture lock mechanism. Streamlined suture shuttling5, Market-leading biomechanical performance,+ 1-4,6,7 with the lowest displacement during cyclic loading++1,3,6,7 The Q-FIX KNOTless all-Sutures Anchor offers a versatile range of suture options that include both single-loaded MinITAPE Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure13,14 or ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor. 공시 • Jun 13
Smith & Nephew plc Appoints David King as an Independent Non-Executive Director and Member of the Compliance & Culture and the Remuneration Committees, Effective 1 July 2025 Smith & Nephew plc announced that David King will join the Board as an independent Non-Executive Director with effect from 1 July 2025. David will serve as a member of the Compliance & Culture and the Remuneration Committees. David is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies including ZimVie (2022 - 2025), VaxCare (2021 - 2025), Privia Health, Health Channels, LGC and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells). 공시 • Jun 10
Smith+Nephew Announces the Introduction of A New Medial Stabilized Insert for Its Legion Total Knee System Smith+Nephew announced the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone- conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient. The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI* Surgical System, and a strong clinical legacy. It's an ideal solution for surgeons looking to align with the principles of personalized care. The LEGION MedialStabilized TKS has demonstrated more than 20 years of clinical success, with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial STabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026. 공시 • May 15
Smith+Nephew Announces A Comparative sNPWT Study of 10,000+ C-sections Shows PICO™ sNPWT Reduces Complications and Cuts Healthcare Costs by $728,000 Per 1,000 Patients Smith+Nephew announced findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and overall costs, compared to another sNPWT device (P=0.05). New survey: The real-life burden of C-section complications: A complementary survey of new mothers who have undergone C-sections highlighted the impact of SSCs on both mother and baby: Mothers with complications reported requiring hospital readmissions; Are 5 times more likely to describe their recovery as traumatic; Over half (55%) reported feeling depressed than those that reported no complications; Are 5.4 times more likely to be unable to breastfeed; Two in three mothers (66.3%) reported that their overall c-section recovery impacted their ability to bond with their baby. Real-world data shows the clinical and economic benefits of using PICO sNPWT in patients undergoing C-section procedures: The study used real-world evidence from the Premier PINC AI™ Healthcare Database to analyze outcomes from a geographically diverse mix of community hospitals, teaching hospitals and healthcare systems across the US. Notable findings include significant reductions with PICO sNPWT, compared to other sNPWT devices in the incidence of: Overall SSIs (p=0.018); Superficial SSIs (p=0.017); Wound dehiscence (p=0.005); Seroma formation(p=0.050). PICO sNPWT is proven to reduce the odds of surgical site infections (SSIs), which could facilitate early mother and baby bonding and positively impacts on the patient’s emotional wellbeing. 공시 • May 02
Smith & Nephew plc Maintains Earnings Guidance for the Full Year 2025 Smith & Nephew plc maintained earnings guidance for the full year of 2025. For the period, the company guidance is unchanged: Underlying revenue growth expected to be around 5.0% (reported growth 5.4%), and significant trading profit margin expansion to between 19.0% and 20.0%. Continued higher cadence of product launches and clinical evidence contributing to growth. Unchanged outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures, and mitigations. 공시 • Apr 25
Smith & Nephew plc Announces Steps Down of Bob White as an Independent Non-Executive Director, Effective 30 April 2025 Smith & Nephew plc announced that Bob White has informed the Board that he will be stepping down as an Independent Non-Executive Director on 30 April 2025 and will not submit himself for re-election at the Company's Annual General Meeting to be held on 30 April 2025. 공시 • Mar 11
Smith & Nephew plc, Annual General Meeting, Apr 30, 2025 Smith & Nephew plc, Annual General Meeting, Apr 30, 2025. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye, watford United Kingdom 공시 • Mar 10
Smith & Nephew plc to Report First Half, 2025 Results on Jul 31, 2025 Smith & Nephew plc announced that they will report first half, 2025 results on Jul 31, 2025 공시 • Jan 14
Smith & Nephew plc Announces Board and Committee Changes Smith+Nephew announced that Sybella Stanley will join the Board as an independent Non-Executive Director with effect from 1 February 2025. Sybella will serve as a member of the Remuneration Committee and will succeed Angie Risley as Chair of the Remuneration Committee with effect from 30 June 2025. Sybella has worked for RELX Plc since 1997 and is currently Director of Corporate Finance. She retired in December 2024 from the Board of Tate & Lyle plc where she served for nine years as an Independent Non-Executive Director and was Chair of the Remuneration Committee. She served for nine years as an Independent Non-Executive Director of Merchants Trust PLC and as Senior Independent Director and Chair of the Remuneration Committee until her retirement in March 2024. She is also co-chair of the Development Board of Somerville College, Oxford. 공시 • Dec 19
Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Smith+Nephew announced its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. The first procedures using CORIOGRAPH Pre- Op Planning and Modeling Services for Hip with RI.HIP solutions were recently completed by Dr. George Haidukewych, Surgeon in Chief and Academic Chairman at Orlando Health Jewett Orthopedic Institute in Orlando, FL. The CORI Surgical System offers proprietary tools and software across the full suite of procedure solutions to deliver a platform that is flexible and scalable across knee and hip joint arthroplasty indications. Built on 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans, CORIOGRAPH Pre-op Planning and Modeling Services for hip is designed to optimize implant planning and personalization, including: Advanced modeling capabilities that utilize patient specific spinopelvic classification and pelvic tilt go beyond the mechanics of simple range-of-motion to simulate activities of daily living that help surgeons make decisions on optimal implant placement. Image-agnostic planning capabilities with 2D and/or 3D images to help personalize the end-to-end care specifically to the patient need. Can be used across the entire spectrum of Smith+Nephew hip implant solutions and technologies. CORIOGRAPH Pre-OP Planning and Modeling Services combined with RI.HIP solutions and the recently launched CADALYSTEM Primary Hip System, offer a complete solution for primary total hip arthroplasty. 공시 • Nov 02
Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025 Smith & Nephew plc provided earnings guidance for the full year 2024 and for 2025. For the full year, company expected underlying revenue growth to be around 4.5% (previously 5.0% to 6.0%), primarily due to the impact of China headwind. For trading profit margin in 2024, company now expecting growth of up to 50bpscompared to last year's 17.5% (previously at least 18.0%), reflecting the reduced operating leverage from slower revenue growth.
For 2025, given the updated 2024 outlook and, in particular, uncertainty around ongoing China headwinds, company now expects to expand trading profit margin significantly to between 19.0% and 20.0%, driven by the continued delivery of the 12-Point Plan improvements. 공시 • Oct 31
Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025 Smith & Nephew plc announced that they will report fiscal year 2024 results on Feb 25, 2025 공시 • Oct 02
Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium) Smith+Nephew announced that its LEGION Hinged Knee (HK) System is now available in the United States with proprietary OXINIUM (Oxidized Zirconium) implant technology that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both. Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. The award winning OXINIUM Technology has demonstrated lower inflammatory response, superior wear resistance and reduced surface damage, and fewer signs of corrosion damage compared to cobalt chrome, ultimately helping to mitigate common risk factors associated with revision procedures. LEGION revision with proprietary OXINIUM Technology has established itself as the best performing bearing with the lowest risk of re-revision compared to the class average. 공시 • Sep 27
Smith+Nephew Announces Board and Committee Changes Smith+Nephew announced that Angie Risley has been appointed as Senior Independent Director with effect from 1 October 2024. She will remain as Chair of the Remuneration Committee and a member of the Nomination & Governance Committee. Ms Risley succeeds Marc Owen who will remain the Chair of the Compliance & Culture Committee, and a member of the Audit and Nomination & Governance Committees. 공시 • Jul 17
Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System Smith+Nephew announced it has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the United States Food and Drug Administration. The system is designed to address the evolving demands of primary hip surgery including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs). Advancements in primary hip arthroplasty include a shift to a shorter, proximally filling stem that is easier to prepare and insert using the direct anterior approach - a less invasive procedure that may enable improved range-of-motion and faster recovery for patients. This segment fits a diverse range of patient anatomies and is rapidly growing at a compound annual growth rate >10%. Building on the heritage of Smith+Nephew's clinically successful stem designs, the CATALYSTEM Primary Hip system was developed using global data sets across femoral morphologies to help deliver a precision fit. Featuring a triple-taper stem design with uniform proximal loading, the reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches. The CATALYSTEM Primary hip System also utilizes proprietary, patent-pending, ACCUBROACH Technology delivering proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating. 공시 • Jul 05
Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.). Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024.Cevian Capital II GP Limited completed the acquisition of 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024. 공시 • May 10
Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024 Smith & Nephew plc announced a final dividend of 23.1 US cents per ordinary share in respect of the year ended 31 December 2023 will be paid on 22 May 2024 to shareholders whose name appeared on the Register at the close of business on 2 April 2024. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 18.49 pence per share. 공시 • May 01
Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024 Smith & Nephew plc announced that they will report first half, 2024 results on Aug 01, 2024 공시 • Apr 02
Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System Smith+Nephew announced the launch of its RENASYS EDGE Negative Pressure Wound Therapy System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn, it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities. It is estimated that the annual financial burden of chronic wounds in the US is $33 billion, and affecting some 8.2 million people. The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated. The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort. Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System - SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this new, innovative technology to more patients on a national level and support its growing negative pressure wound therapy business. For clinicians, the RENASYS EDGE system is intuitive and easy-to-use. Its user-friendly interface gives step-by-step guidance on therapy application, and technical support is just one click away during set up with the near field communication feature on the system. Additionally, Smith+Nephew provides 24-hour customer support for patients and a clinical hotline. 공시 • Mar 12
Smith & Nephew plc, Annual General Meeting, May 01, 2024 Smith & Nephew plc, Annual General Meeting, May 01, 2024, at 11:00 Coordinated Universal Time. Location: Smith+Nephew Academy London, Building 5, Croxley Park, Hatters Lane, Watford, WD18 8YE Watford, London United Kingdom 공시 • Dec 07
Smith+Nephew Announces Board Changes Smith+Nephew announced that Rick Medlock has notified the Board of his decision not to submit himself for re-election as a Non-Executive Director at the next annual general meeting of the Company. Jez Maiden, Non-Executive Director, will be appointed Chair of the Audit Committee with effect from 1 March 2024. The Board would like to thank Rick for his commitment and contribution to the Board and the Company and to congratulate Jez on his new appointment. joined the Board in 2023 and has extensive financial experience across a diverse range of industries and sectors. Jez was Chief Financial Officer of 5 UK-listed companies over a period of 24 years and has served as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He was previously Chair of the Audit Committee at Synthomer PLC and PZ Cussons plc. Current external appointments; Senior Independent Director, Travis Perkins plc. Non-Executive Director and member of the Audit Committee at Intertek Group plc. Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants. 공시 • Nov 24
Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million. Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million on November 22, 2023. Under the terms of transaction, initial cash consideration of $180 million at closing and up to a further $150 million contingent on financial performance will be paid. The acquisition will be financed from existing cash and debt facilities. All CartiHeal employees are expected to transfer to Smith+Nephew. The transaction is expected to close in the first quarter of 2024. 공시 • Nov 04
Smith & Nephew plc Provides Earning Guidance for Full Year 2023 Smith & Nephew plc provided earning guidance for full year 2023. For the period, underlying revenue growth currently expected to be towards the higher end of guided range of 6.0% to 7.0% and trading profit margin now expected to be around 17.5%, reflecting headwinds from china. 공시 • Nov 02
Smith & Nephew plc Announces Appointment of John Rogers as CFO Smith & Nephew plc announced that John Rogers will succeed Anne-Françoise Nesmes as Chief Financial Officer. He will join the company as Chief Financial Officer-designate on 1 December 2023 and, following a period of induction, will join the Board as Chief Financial Officer in the first quarter of 2024. Anne-Françoise's intention to step down as Chief Financial Officer was announced on 3 August 2023, and she has agreed to remain on the Board to finalise the 2023 Annual Report and Accounts and support an effective transition. John has extensive financial and commercial leadership experience across a range of sectors and on a global basis, as well as a track record of delivering complex international transformation programmes. He has served as the Chief Financial Officer of two FTSE-100 companies. He was most recently Chief Financial Officer at WPP plc where he successfully led the implementation of their global transformation programme. Prior to WPP, John was Chief Financial Officer at J Sainsbury plc and also served as Chief Executive Officer ofArgos, Habitat and Sainsbury's clothing and general merchandise businesses, where he led a major digitisation programme, driving increased market share and double-digit profit growth. 공시 • Oct 22
Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023 Smith & Nephew plc announced on 3 August 2023, an interim dividend for 2023 of 14.4 US cents per ordinary share will be paid on 1 November 2023 to shareholders whose names appeared on the Register at the close of business on 6 October 2023. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 11.89 pence per share. 공시 • Sep 14
Smith & Nephew plc Announces Board and Committee Changes Smith+Nephew announced that Jeremy (Jez) Maiden and Simon Lowth will be joining the Board as independent Non-Executive Directors. Jez joins and will serve as a member of the Audit Committee and Remuneration Committee. Simon will join on 1 January 2024 and will serve as a member of the Audit Committee and Nomination & Governance Committee. Additionally,Rupert Soames will, as planned,assume the role as Chair of the Board on 15 September, in succession to Roberto Quarta. Rupert has also been appointed as Chair of the Nomination & Governance Committee and will continue to serve on the Remuneration Committee. Jez Maiden has extensive global financial experience across a diverse range of industries and sectors. He retired earlier this year as Group Finance Director at Croda International, the FTSE-100 global speciality chemicals company, and before that held similar roles at National Express Group and Northern Foods. He is currently Senior Independent Director at Travis Perkins plc and a Non-Executive Director and member of the Audit Committee at Intertek Group plc. Previously, he served as the Senior Independent Director at Synthomer and at both PZ Cussons and Synthomer he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants. Simon Lowthhas deep experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions.He currently serves as Group Chief Financial officer of BT Group, a role he has held since 2016 and previously performed the same role at BG Group, AstraZeneca and Scottish Power.Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK and has a background in engineering. He previously served as a Non-Executive Director on the Board of Standard Chartered. He currently holds no additional external appointments. 공시 • Aug 04
Smith & Nephew plc Increases Revenue Guidance for 2023 Smith & Nephew plc announced full year guidance for 2023. For the year, the company expects revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%). 공시 • Aug 03
Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer Smith & Nephew plc announced that Anne-Françoise Nesmes has informed the Board of her intention to step down as Chief Financial Officer during the second quarter of 2024, on a date to be agreed. The Board has initiated an external search for her successor. 공시 • Jun 13
Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System Smith+Nephew announced that it has received 510(k) clearance from the United States Food and Drug Administration for its AETOS Shoulder System. Designed to restore patients' range-of-motion1-4 and help minimize arthritic shoulder pain. Features the AETOS Meta Stem - designed to maximize stability, preserve bone, and maintain patient anatomy. Indicated for both anatomic and reverse total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. For healthcare professionals, the AETOS Shoulder System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion and fewer instruments for primary anatomic and reverse, the system is designed to simplify the operating room flow. The AETOS Shoulder System is the latest solution in Smith+Nephew's expanding Upper Extremity portfolio and complements market leading Sports Medicine shoulder repair and biologics solutions. 공시 • Nov 04
Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023 Smith & Nephew plc announced that they will report fiscal year 2022 results on Feb 21, 2023 
